Erica Boliek Joins CellMark Biopharma as Global Chief of Research & Development

CellMark Biopharma is a global innovator in medical nutrition combining scientifically based medical research with innovative multi-platform technology creating the safest and most therapeutically advanced products to those desiring relief from cancer and cancer related side effects such as cancer cachexia and chemo brain.


CellMark Biopharma, the leading biotech company ‘Fueling the Fight Against Cancer’, today announced that Erica Boliek, M.M.S., PA-C, joined CellMark Biopharma as the company’s Chief Research & Development.


“Erica is truly an outstanding individual that excels at everything she pursues, we are very fortunate to have her join our team,” stated Derek Vest, founder and CEO of CellMark Biopharma. “Erica’s vast experience and knowledge of science based medicine has already helped CellMark take the lead position with innovative products designed for cancer patients. We look forward to Erica’s research as we announce new products and expand into other sectors in 2016.”


As Chief of Research & Development, Ms. Boliek leads CellMark’s R&D division with access to millions of medical documents and clinical trails providing CellMark with an added advantage over other companies that have sought to create similar products but have failed.


Ms. Erica Boliek, M.M.S., PA-C, CPCC is a clinician-scientist who has spent her time cultivating a broad experience in research, globally. Among her other credentials are Board Certified Athletic Trainer, a Certified Cancer Coach, and manuscript reviewer for the Journal of Athletic Training and the American College of Sports Medicine. She is also published works in the Journal of American Academy of Physician Assistants and lectured globally.


Her work has been focused on brain trauma and she has been invited multiple times to work/speak at the Consensus Conference on Concussion in Sport in Zurich, Switzerland and played an integral part in the working group for the module changes in SCAT 3 testing (a standardized tool for evaluating concussions). Further, Ms. Boliek has both lectured and led workshops at several conferences on Pediatric Concussions & Injury Prevention, including the 2012 and 2013 International Pediatric Orthopedic Society. She was the Key Note Speaker for the 2014 ATAF Annual Symposium for Concussion Evaluation and Management as well. Her personal favorite lecture she gave was at Oxford University delivered entirely in Latin.


She has helped lead the design, development and implementation of the Concussion and Sports Medicine Program for the Lee Memorial Health System and Lee County Schools. She was involved early on in her career with the Children’s Hospital of Pennsylvania in the Pediatric and Adolescent Research Department for Concussion Management and Intervention. She helped facilitate the implementation of ImPACT® Concussion Testing.


Her extensive background in clinical research, solutions development based on mass data analysis, and true pathophysiology solutions enable her to lead an international group of scientists and formulators to generate clinically significant products. She serves on multiple boards of both hospitals and private institutions.


INDUSTRY KEYWORDS: Biotechnology, Biotech, Cancer, cachexia, chemo brain, chemo fog, Derek Vest, Craig Pisaris-Henderson, Erica Boliek, cancer super drink, Clinical Trials, Oncology, CellMark Biopharma, CellAssure, Cognify Kalos Therapeutics, Dr. Stan Headley, Daniel Von Hoff, Stand Up To Cancer, Pharmaceutical, Research, Health, malnutrition, medical nutrition, Palliative Care


Release ID: 100109